UNSPSC 51334106: Perospirone hydrochloride hydrate

This classification denotes an anxiolytic with the molecular formula C23H30N4O2S.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S03S4466IP, chemically known as cis-n-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximide hydrochloride dihydrate, but more generally known as perospirone hydrochloride hydrate, which bears US NIH Compound Identifier 5282504.

European Medicines Agency schedules perospirone hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09735MIG. Most nations, for tariff purposes, schedule perospirone hydrochloride hydrate under HS 29341000. SMILES: C1CCC2C(C1)C(NS2)N3CCN(CC3)CCCCN4C(=O)[C@@H]5CCCC[C@@H]5C4=O.O.O.CL.

UNSPSC 51334106 Perospirone hydrochloride hydrate is a Commodity code that nominally covers a specific antipsychotic pharmaceutical agent, but recent state and local procurement activity under this code shows minimal relevance to the narrow chemical name; the three most recent opportunities posted involve procurement of naloxone and drug deactivation systems, a direct-to-manufacturer prescription pharmacy initiative, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The mismatch suggests that state and local buyers and procurement platforms are either applying this code as a catch-all for pharmaceutical procurement broadly or the opportunities are mistagged. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in Minnesota and Oregon). The procurement mix reflects diverse pharmaceutical-acquisition strategies: direct procurement of harm-reduction and deactivation systems for community health, exploratory market outreach for direct-to-manufacturer contracting outside traditional PBM and GPO channels, and cooperative volume purchasing of generic pharmaceuticals through authorized wholesalers.

Geographic activity centers on Florida, Texas, and Minnesota with participation from Oregon through the cooperative purchasing vehicle. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023), the Texas Health and Human Services Commission's RFI regarding direct-to-manufacturer prescription programs (response deadline April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and an effective contract date of July 1, 2026. The cooperative purchasing opportunity requires vendors to supply through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), achieve availability by May 15, 2026, and accept a 3 percent administrative fee; evaluation weights price competitiveness at 75 percent and administrative compliance at the remainder. No explicit set-aside designations appear in the recent postings.